Tarsus Pharmaceuticals annual current ratio
2019
2020
2021
2022
2023
2024
2025
Tarsus Pharmaceuticals Current Ratio Growth & History (TARS)
Tarsus Pharmaceuticals's current ratio was 3.85 for fiscal 2025.
View full Tarsus Pharmaceuticals company overviewTarsus Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 3.85 | −0.57 | −12.93% |
| 2024 | 2024-12-31 | 4.42 | −2.51 | −36.19% |
| 2023 | 2023-12-31 | 6.93 | −7.67 | −52.53% |
| 2022 | 2022-12-31 | 14.61 | −0.72 | −4.71% |
| 2021 | 2021-12-31 | 15.33 | −16.35 | −51.61% |
| 2020 | 2020-12-31 | 31.68 | −39.18 | −55.29% |
| 2019 | 2019-12-31 | 70.85 | — | — |
Tarsus Pharmaceuticals quarterly current ratio
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.20 | −2.06 | −39.17% |
| Q1 2026 | 2026-03-31 | 3.74 | −1.83 | −32.80% |
| Q4 2025 | 2025-12-31 | 3.85 | −0.57 | −12.93% |
| Q3 2025 | 2025-09-30 | 4.29 | −1.14 | −20.94% |
| Q2 2025 | 2025-06-30 | 5.26 | −1.77 | −25.23% |
| Q1 2025 | 2025-03-31 | 5.57 | −2.44 | −30.47% |
| Q4 2024 | 2024-12-31 | 4.42 | −2.51 | −36.19% |
| Q3 2024 | 2024-09-30 | 5.42 | −5.73 | −51.38% |
| Q2 2024 | 2024-06-30 | 7.03 | −5.40 | −43.42% |
| Q1 2024 | 2024-03-31 | 8.01 | −7.73 | −49.10% |
| Q4 2023 | 2023-12-31 | 6.93 | −7.67 | −52.53% |
| Q3 2023 | 2023-09-30 | 11.15 | −5.25 | −32.00% |
| Q2 2023 | 2023-06-30 | 12.43 | −8.93 | −41.82% |
| Q1 2023 | 2023-03-31 | 15.74 | 1.57 | +11.04% |
| Q4 2022 | 2022-12-31 | 14.61 | −0.72 | −4.71% |
| Q3 2022 | 2022-09-30 | 16.40 | −1.65 | −9.14% |
| Q2 2022 | 2022-06-30 | 21.36 | 2.14 | +11.15% |
| Q1 2022 | 2022-03-31 | 14.18 | −4.75 | −25.08% |
| Q4 2021 | 2021-12-31 | 15.33 | −16.35 | −51.61% |
| Q3 2021 | 2021-09-30 | 18.05 | 3.55 | +24.50% |
| Q2 2021 | 2021-06-30 | 19.22 | — | — |
| Q1 2021 | 2021-03-31 | 18.92 | — | — |
| Q4 2020 | 2020-12-31 | 31.68 | −39.18 | −55.29% |
| Q3 2020 | 2020-09-30 | 14.50 | — | — |
| Q4 2019 | 2019-12-31 | 70.85 | — | — |
Tarsus Pharmaceuticals current ratio trends
Over the last five fiscal years, Tarsus Pharmaceuticals's current ratio decreased from 31.68 to 3.85, a change of −27.83. The latest reported quarter, Q2 2026, shows 3.20.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tarsus Pharmaceuticals source filings ↗